Pulmonary zygomycosis is a relatively uncommon complication of solid organ or peripheral blood stem cell transplantation and has a high associated mortality. Optimal therapy consists of complete resection of infected tissue and treatment with amphotericin B (AmB). We describe two patients, one of whom underwent orthotopic heart transplantation and the other who received a peripheral blood stem cell transplant, who were diagnosed with invasive pulmonary zygomycosis. Both patients were treated with a liposomal preparation of AmB and early partial resection of the infected structures followed by prolonged posaconazole maintenance therapy. Despite incomplete resection, this treatment regimen resulted in a favourable outcome in both patients, including survival of more than 17 months in one patient at last follow up. For patients in whom complete resection of pulmonary zygomycosis is not possible, subtotal resection and treatment with liposomal AmB followed by therapy with posaconazole may be an effective treatment option.
Introduction
Pulmonary zygomycosis is a rare complication of transplantation with an associated mortality of up to 50% when treated with amphotericin B (AmB) alone (Almyroudis N, Sutton D, Linden P, Rinaldi M, Fung J, Kusne S. Am J Transplant 2006; 6: 2365-74). Complete excision of infected tissue, combined with the administration of liposomal AmB has been shown to reduce mortality to 6% in patients with isolated pulmonary infection (Almyroudis N, Sutton D, Linden P, Rinaldi M, Fung J, Kusne S. Am J Transplant 2006; 6: 2365-74). The role of surgical debridement for patients with unresectable disease remains unclear. The role of the new triazole agent, posaconazole for the treatment of infections with zygomycetes is also yet to be defined. In this report, we present two transplant recipients (one solid organ transplant and one allogeneic stem cell transplant) with invasive pulmonary zygomycosis. Because of the disease extent and anatomical structures involved in the infection, both patients could only undergo subtotal resection of infected tissue. Each patient was treated with liposomal amphotericin B (Ambisome) followed by a prolonged course of posaconazole and had a favourable response to therapy. posterior chest wall tenderness and a non-productive cough while on maintenance immunosupression with tacrolimus and prednisone 10 mg twice per day. A computed tomography (CT) scan demonstrated multilobar infiltrates, cavitary masses in the right upper lobe and right ninth rib destruction with an associated mass (Fig. 1) . Culture of aspirated fluid from a right sided pleural effusion yielded Mucor spp. The patient underwent right lateral chest wall resection. Complete resection could not be achieved because of extensive chest wall involvement and multi-lobar disease with pleural infection. Histology from operative specimens was consistent with invasive zygomycosis. Multiple intraoperative cultures of tissue and fluid yielded Mucor spp. The patient was initially treated with a 12-day course of liposomal AmB (Ambisome) 10 mg kg )1 day )1 , which was discontinued because of nephrotoxicity (increase of creatinine from 1.8 to 2.6 mg dl A 32-year-old man, 34 days status postallogeneic bone marrow transplant (BMT) for aplastic anaemia complicated by engraftment syndrome and grade II graftversus-host disease (GVHD) of skin treated with tacrolimus, Enbrel, and medrol with voriconazole antifungal prophylaxis, presented with a persistent cough. Absolute neutrophil count was 2700 mm )3 and the absolute lymphocyte count was 500 mm )3 . A chest CT scan revealed a mass surrounding the right lower lobe (RLL) bronchus with an adjacent RLL pulmonary artery aneurysm (Fig. 3) . The aneurysm was coil embolised and the next day a RLL and right middle lobe bilobectomy was performed. Pathological examination revealed aseptate hyphae with broad angle branching consistent with zygomycosis with pulmonary artery and bronchial invasion (Fig. 4) . Unresectable fungal tissue invaded the hilum, which would have necessitated a pneumonectomy in an infected field. A culture was not performed at the time of the operation. The patient received 4 weeks of therapy with liposomal AmB 10 mg kg )1 day )1 , which was discontinued when an adequate radiographic response was documented and it was necessary to initiate treatment with foscarnet. After amphotericin was discontinued, treatment with posaconazole 200 mg p.o. four times per day was initiated. He returned 1 month later with methicillin-resistant Staphylococcus aureus bacteraemia. On POD 109, the patient died from sepsis. An autopsy was declined by the family.
Discussion
These case reports demonstrate a successful outcome to treatment of invasive pulmonary zygomycosis in the setting of immune suppression with the use of partial surgical debridement and therapy with AmB followed by long-term treatment with oral posaconazole. Although the incidence of invasive infection with zygomycetes is generally reported to be less than 1% in most transplant centres ( . With increasing incidence, as well as an overall high mortality, there is an urgent need to identify more optimal strategies for the management of infection with zygomycetes.
The traditional approach to therapy has consisted of complete surgical resection of infected tissue with the concomitant administration of an AmB product (Tedder M, Spratt J, Anstadt M et al., Ann Thorac Surg 1994; 57: 1044-50). Often, however, invasive fungal infections cross tissue planes and can involve multiple noncontiguous structures, which complicate decisions regarding surgical debridement. In many cases, if complete resection of the involved tissue cannot be accomplished, surgical intervention is deferred. Many studies have demonstrated the benefit of debridement, particularly with pulmonary disease. Mortality was reduced from 50% with AmB alone to 6.6% with AmB plus surgery for pulmonary zygomycosis in one retrospective review of solid organ transplant recipients (although patients with fewer comorbidities were more likely to be the candidates for surgery) (Almyroudis N, Sutton D, Linden P, Rinaldi M, Fung J, Kusne S. Am J Transplant 2006; 6: 2365-74). In another small study of solid organ transplant recipients, the two patients with pulmonary zygomycosis who underwent surgical resection survived, while the two who did not expired (Stelzmueller I, Lass-Floerl C, Geltner C et al., Transpl Internat 2008; 21: 534-46) . A study in renal transplant recipients, however, did not demonstrate such a beneficial effect. Of four patients with pulmonary disease, only one of the three patients who underwent upper lobectomy or wedge resection survived (Forrest G, Mankes K. Transpl Infect Dis 2007; 9: 161-4). Because invasive zygomycosis is rare, clinical decisions with regards to management are often reliant upon case reports as it is not possible to conduct prospective trials. Our case report combined with the above reported experience suggests that partial resection combined with medical therapy is a reasonable option for patients in whom complete resection is not possible.
Clearly, appropriate antifungal therapy also remains an important component of treatment. Although some species such as Cunninghamella are less responsive to antifungal therapy of any type, an amphotericin product is considered the first line therapy for all zygomycete species (Ribes J, Vanover-Sams C, Baker D. Clin Microbiol Rev 2000; 13: 236-301). A recent study has shown that the timing of the initiation of therapy is also critical to outcomes. In patients with haematological malignancy with zygomycosis, a delay in treatment by greater than 6 days doubled 12-week mortality compared with those who received prompt initiation of therapy (Chamilos G, Lewis R, Kontoyiannis D. Clin Infect Dis 2008; 47: 503-9). In this same study, posaconazole use after initial treatment with amphotericin was associated with a favourable outcome (Chamilos G, Lewis R, Kontoyiannis D. Clin Infect Dis 2008; 47: 503-9). Posaconazole has been shown to have in vitro activity against zygomycetes with MIC 50 levels of 1 lg ml )1 or less for these organisms (Sabatelli F, Patel It would therefore appear that optimal therapy for pulmonary invasive zygomycete infection in the setting of significant immune compromise such as solid organ transplantation or bone marrow transplant would involve a combination of the prompt initiation of an AmB preparation followed by complete or partial surgical debridement. A course of therapy with AmB could be followed by treatment with posaconazole until complete clinical resolution of the infection is documented radiographically. As most transplant patients require long-term immune suppression, the ultimate duration of oral therapy remains unclear because relapse of fungal infections can occur. The role of combination antifungal therapy has not yet been clarified; however, this may be an attractive option for refractory cases.
